Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VP-102 Cantharidin topical film forming solution
VP-102 Cantharidin film forming · 1 trial · 12 indications
Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84).
Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84).
| Arm | Type | Description |
|---|---|---|
| VP-102 | EXPERIMENTAL | Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. |
| Name | Type | Description |
|---|---|---|
| VP-102 Cantharidin topical film forming solution | COMBINATION_PRODUCT | VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments. |
| VP-102 Cantharidin, topical film forming solution | COMBINATION_PRODUCT | VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments. |
Inclusion Criteria: 1. Be healthy, immunocompetent males or females at least 2 years of age and older for Cohort 1 and 12 years of age and older for Cohort 2. 2. Present with 1-6 common warts (verruca vulgaris) located anywhere on the body except for the following prohibited areas: the eye area (in...
VP-102 Cantharidin film forming is an investigational small molecule therapy being studied for the treatment of common warts, including warts on the hands and verruca vulgaris. It is applied as a topical film forming solution. The drug is in Phase 2 clinical development and has not been approved by the FDA.
VP-102 Cantharidin film forming is being developed by Verrica Pharmaceuticals Inc., which trades on the Nasdaq under the ticker symbol VRCA. Verrica is the sponsor of the clinical program evaluating this topical cantharidin formulation for common warts.
VP-102 Cantharidin film forming is in Phase 2 clinical development. One Phase 2 trial has been completed, and there are currently no active trials listed for this asset. The drug remains investigational and has not received FDA approval for any indication.
VP-102 Cantharidin film forming has been evaluated in one completed Phase 2 trial, NCT03487549, titled Cantharidin and Occlusion in Verruca Epithelium. The trial enrolled 56 participants in the United States and studied common warts, hand warts, and verruca vulgaris. It was an uncontrolled study without randomization or double blinding.
Yes, VP-102 Cantharidin film forming is also known as VP-102 Cantharidin topical film forming solution. Both names refer to the same investigational topical product developed by Verrica Pharmaceuticals for common warts.